Global Targeted Protein Degradation Market By Offering (Active Degraders (PROTACs), LYTAC (Lysosome Targeting Chimera) Technology, Autophagosome-tethering Compound (ATTEC), Autophagy-targeting Chimera (AUTAC) System, TAG Degradation Platform (aRAG, dTAG), Degrader Building Blocks, Ubiquitin Proteasome System Proteins and Assays, Assays for Protein Degradation, Custom Degrader Services, SARDS and SERDs, Others); By Potential Targets (Intracellular Proteins, Extracellular Proteins; Transmembrane Proteins, Intracellular Proteins; Damaged Organelles Associated with Specific Proteins, Intracellular Proteins; Non-protein Autophagy Substrates); By Type of Diseases (Breast Cancer, Colorectal Cancer, Prostate Cancer, Alzheimer’s disease, Liver Fibrosis, Parkinson’s disease, Psoriasis, Rheumatoid Arthritis, Autoimmune Diseases, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Global targeted protein degradation market is expected to achieve CAGR of 9.6% over the forecast period. Medical science is witnessing massive developments as it is truly the need of the hour. New types of treatments are being sought to bring down the costs and increase the efficiency to battle several diseases. One such treatment is targeted protein degradation. Proteins are essential part of our lives. Right from helping in wear and tear of muscles to building new ones. It is undoubtedly the most macro nutrient and essential building block along with carbohydrates and fats. Its use in several treatments is driving the growth of the targeted protein degradation market. This process is done by using PROTAC molecules to complete knocking down of target protein located within cells.
The world suffered huge losses and secured huge losses courtesy of the dreadful COVID-19 pandemic. On the other hand, the targeted protein degradation market witnessed massive growth as new types of remedies and treatments were explored to get rid the highly infectious SARS-COV2 virus. The market is expected to continue the momentum it got in the times of pandemic.
Offering Outlook
On the basis of offering, the targeted protein degradation market has been divided into active degraders (PROTACs), LYTAC (Lysosome Targeting Chimera) technology, autophagosome-tethering compound (ATTEC), autophagy-targeting chimera (AUTAC) system, TAG degradation platform (aTAG, dTAG), degrade building blocks, ubiquition proteasome system proteins and assays, assays for protein degradation, custom degrader services, SARDS and SERDs, and others. The active degraders (PROTACs) generates maximum amount of revenue for this market. These degraders comprise of binding moieties for target protein along with E3 ubiquitin ligase through a linker.
Global Targeted Protein Degradation Market Revenue & Forecast, (US$ Million), 2022 – 2030
Potential Targets Outlook
On the basis of potential targets, the targeted protein degradation market has been segmented into intracellular proteins, extracellular proteins; transmembrane proteins, intracellular proteins; damaged organelles associated with specific proteins and intracellular proteins; non-protein autophagy substrates. Intracellular proteins are found to be more effective and hence dominate in terms of market share.
Type of Diseases Outlook
On the basis of diseases, the targeted protein degradation market has been divided into breast cancer, colorectal cancer, prostate cancer, Alzheimer’s disease, liver fibrosis, Parkinson’s disease, psoriasis, rheumatoid arthritis, autoimmune diseases and others. Cancer starts to damage body from cellular level and several studies have proven that targeted protein degradation is actually effective in the dreadful disease.
Region Outlook
On the basis of region, the targeted protein degradation market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of North America makes most of the money for this market. Presence of top-class hospitals and medical research centres along with higher level of income is the reason why this region dominates in terms of highest share.
Competitive Landscape
The report provides both, qualitative and quantitative research of targeted protein degradation market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the targeted protein degradation market are listed below:
- Almac Group
- Amgen Inc.
- Arvinas
- Bayer AG
- C4 Therapeutics
- Captor Therapeutics
- Genentech, Inc.
- GlaxoSmithKline plc.
- KYMERA THERAPEUTICS
- Promega Corporation
- Other Market Participants
Global Targeted Protein Degradation Market
By Offering
- Active Degraders (PROTACs)
- LYTAC (Lysosome Targeting Chimera) Technology
- Autophagosome-tethering Compound (ATTEC)
- Autphagy-targeting Chimera (AUTAC) System
- TAG Degradation Platform (aTAG, dTAG)
- Degrader Building Blocks
- Ubiquitin Proteasome System Proteins and Assays
- Assays for Protein Degradation
- Custom Degrader Services
- SARDs and SERDs
- Others
By Potential Targets
- Intracellular Proteins
- Extracellular Proteins; Transmembrane Proteins
- Intracellular Protiens; Damaged Organelles Associated with Specific Proteins
- Intracellular Proteins; Non-protein Autophagy Substrates
By Type of Diseases
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Alzheimer’s disease
- Liver Fibrosis
- Parkinson’s disease
- Psoriasis
- Rheumatoid Arthritis
- Autoimmune Diseases
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Targeted Protein Degradation Market
6. Market Synopsis: Targeted Protein Degradation Market
7. Targeted Protein Degradation Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Targeted Protein Degradation Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Targeted Protein Degradation Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Targeted Protein Degradation Market
8. Global Targeted Protein Degradation Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Targeted Protein Degradation Market Revenue (US$ Mn)
8.2. Global Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1. Active Degraders (PROTACs)
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 – 2021
8.2.1.3. Market Forecast, 2022 – 2030
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 – 2021
8.2.1.5.1.2. Market Forecast, 2022 – 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 – 2021
8.2.1.5.2.2. Market Forecast, 2022 – 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 – 2021
8.2.1.5.3.2. Market Forecast, 2022 – 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 – 2021
8.2.1.5.4.2. Market Forecast, 2022 – 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 – 2021
8.2.1.5.5.2. Market Forecast, 2022 – 2030
8.2.2. LYTAC (Lysosome Targeting Chimera) Technology
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 – 2021
8.2.2.3. Market Forecast, 2022 – 2030
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 – 2021
8.2.2.5.1.2. Market Forecast, 2022 – 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 – 2021
8.2.2.5.2.2. Market Forecast, 2022 – 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 – 2021
8.2.2.5.3.2. Market Forecast, 2022 – 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 – 2021
8.2.2.5.4.2. Market Forecast, 2022 – 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 – 2021
8.2.2.5.5.2. Market Forecast, 2022 – 2030
8.2.3. Autophagosome-tethering Compound (ATTEC)
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 – 2021
8.2.3.3. Market Forecast, 2022 – 2030
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 – 2021
8.2.3.5.1.2. Market Forecast, 2022 – 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 – 2021
8.2.3.5.2.2. Market Forecast, 2022 – 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 – 2021
8.2.3.5.3.2. Market Forecast, 2022 – 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 – 2021
8.2.3.5.4.2. Market Forecast, 2022 – 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 – 2021
8.2.3.5.5.2. Market Forecast, 2022 – 2030
8.2.4. Autophagy-targeting Chimera (AUTAC) System
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2015 – 2021
8.2.4.3. Market Forecast, 2022 – 2030
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015 – 2021
8.2.4.5.1.2. Market Forecast, 2022 – 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 – 2021
8.2.4.5.2.2. Market Forecast, 2022 – 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015 – 2021
8.2.4.5.3.2. Market Forecast, 2022 – 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2015 – 2021
8.2.4.5.4.2. Market Forecast, 2022 – 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015 – 2021
8.2.4.5.5.2. Market Forecast, 2022 – 2030
8.2.5. TAG Degradation Platform (aTAG, dTAG)
8.2.5.1. Definition
8.2.5.2. Market Estimation and Penetration, 2015 – 2021
8.2.5.3. Market Forecast, 2022 – 2030
8.2.5.4. Compound Annual Growth Rate (CAGR)
8.2.5.5. Regional Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 – 2021
8.2.5.5.1.2. Market Forecast, 2022 – 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 – 2021
8.2.5.5.2.2. Market Forecast, 2022 – 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 – 2021
8.2.5.5.3.2. Market Forecast, 2022 – 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 – 2021
8.2.5.5.4.2. Market Forecast, 2022 – 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 – 2021
8.2.5.5.5.2. Market Forecast, 2022 – 2030
8.2.6. Degrader Building Blocks
8.2.6.1. Definition
8.2.6.2. Market Estimation and Penetration, 2015 – 2021
8.2.6.3. Market Forecast, 2022 – 2030
8.2.6.4. Compound Annual Growth Rate (CAGR)
8.2.6.5. Regional Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market Estimation, 2015 – 2021
8.2.6.5.1.2. Market Forecast, 2022 – 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market Estimation, 2015 – 2021
8.2.6.5.2.2. Market Forecast, 2022 – 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market Estimation, 2015 – 2021
8.2.6.5.3.2. Market Forecast, 2022 – 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market Estimation, 2015 – 2021
8.2.6.5.4.2. Market Forecast, 2022 – 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market Estimation, 2015 – 2021
8.2.6.5.5.2. Market Forecast, 2022 – 2030
8.2.7. Ubiquitin Proteasome System Proteins and Assays
8.2.7.1. Definition
8.2.7.2. Market Estimation and Penetration, 2015 – 2021
8.2.7.3. Market Forecast, 2022 – 2030
8.2.7.4. Compound Annual Growth Rate (CAGR)
8.2.7.5. Regional Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market Estimation, 2015 – 2021
8.2.7.5.1.2. Market Forecast, 2022 – 2030
8.2.7.5.2. Europe
8.2.7.5.2.1. Market Estimation, 2015 – 2021
8.2.7.5.2.2. Market Forecast, 2022 – 2030
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market Estimation, 2015 – 2021
8.2.7.5.3.2. Market Forecast, 2022 – 2030
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market Estimation, 2015 – 2021
8.2.7.5.4.2. Market Forecast, 2022 – 2030
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market Estimation, 2015 – 2021
8.2.7.5.5.2. Market Forecast, 2022 – 2030
8.2.8. Assays for Protein Degradation
8.2.8.1. Definition
8.2.8.2. Market Estimation and Penetration, 2015 – 2021
8.2.8.3. Market Forecast, 2022 – 2030
8.2.8.4. Compound Annual Growth Rate (CAGR)
8.2.8.5. Regional Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market Estimation, 2015 – 2021
8.2.8.5.1.2. Market Forecast, 2022 – 2030
8.2.8.5.2. Europe
8.2.8.5.2.1. Market Estimation, 2015 – 2021
8.2.8.5.2.2. Market Forecast, 2022 – 2030
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market Estimation, 2015 – 2021
8.2.8.5.3.2. Market Forecast, 2022 – 2030
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market Estimation, 2015 – 2021
8.2.8.5.4.2. Market Forecast, 2022 – 2030
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market Estimation, 2015 – 2021
8.2.8.5.5.2. Market Forecast, 2022 – 2030
8.2.9. Custom Degrader Services
8.2.9.1. Definition
8.2.9.2. Market Estimation and Penetration, 2015 – 2021
8.2.9.3. Market Forecast, 2022 – 2030
8.2.9.4. Compound Annual Growth Rate (CAGR)
8.2.9.5. Regional Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market Estimation, 2015 – 2021
8.2.9.5.1.2. Market Forecast, 2022 – 2030
8.2.9.5.2. Europe
8.2.9.5.2.1. Market Estimation, 2015 – 2021
8.2.9.5.2.2. Market Forecast, 2022 – 2030
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market Estimation, 2015 – 2021
8.2.9.5.3.2. Market Forecast, 2022 – 2030
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market Estimation, 2015 – 2021
8.2.9.5.4.2. Market Forecast, 2022 – 2030
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market Estimation, 2015 – 2021
8.2.9.5.5.2. Market Forecast, 2022 – 2030
8.2.10. SARDs and SERDs
8.2.10.1. Definition
8.2.10.2. Market Estimation and Penetration, 2015 – 2021
8.2.10.3. Market Forecast, 2022 – 2030
8.2.10.4. Compound Annual Growth Rate (CAGR)
8.2.10.5. Regional Bifurcation
8.2.10.5.1. North America
8.2.10.5.1.1. Market Estimation, 2015 – 2021
8.2.10.5.1.2. Market Forecast, 2022 – 2030
8.2.10.5.2. Europe
8.2.10.5.2.1. Market Estimation, 2015 – 2021
8.2.10.5.2.2. Market Forecast, 2022 – 2030
8.2.10.5.3. Asia Pacific
8.2.10.5.3.1. Market Estimation, 2015 – 2021
8.2.10.5.3.2. Market Forecast, 2022 – 2030
8.2.10.5.4. Middle East and Africa
8.2.10.5.4.1. Market Estimation, 2015 – 2021
8.2.10.5.4.2. Market Forecast, 2022 – 2030
8.2.10.5.5. Latin America
8.2.10.5.5.1. Market Estimation, 2015 – 2021
8.2.10.5.5.2. Market Forecast, 2022 – 2030
8.2.11. Others
8.2.11.1. Definition
8.2.11.2. Market Estimation and Penetration, 2015 – 2021
8.2.11.3. Market Forecast, 2022 – 2030
8.2.11.4. Compound Annual Growth Rate (CAGR)
8.2.11.5. Regional Bifurcation
8.2.11.5.1. North America
8.2.11.5.1.1. Market Estimation, 2015 – 2021
8.2.11.5.1.2. Market Forecast, 2022 – 2030
8.2.11.5.2. Europe
8.2.11.5.2.1. Market Estimation, 2015 – 2021
8.2.11.5.2.2. Market Forecast, 2022 – 2030
8.2.11.5.3. Asia Pacific
8.2.11.5.3.1. Market Estimation, 2015 – 2021
8.2.11.5.3.2. Market Forecast, 2022 – 2030
8.2.11.5.4. Middle East and Africa
8.2.11.5.4.1. Market Estimation, 2015 – 2021
8.2.11.5.4.2. Market Forecast, 2022 – 2030
8.2.11.5.5. Latin America
8.2.11.5.5.1. Market Estimation, 2015 – 2021
8.2.11.5.5.2. Market Forecast, 2022 – 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Offering
9. Global Targeted Protein Degradation Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
9.2.1. Intracellular Proteins
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 – 2021
9.2.1.3. Market Forecast, 2022 – 2030
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 – 2021
9.2.1.5.1.2. Market Forecast, 2022 – 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 – 2021
9.2.1.5.2.2. Market Forecast, 2022 – 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 – 2021
9.2.1.5.3.2. Market Forecast, 2022 – 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 – 2021
9.2.1.5.4.2. Market Forecast, 2022 – 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 – 2021
9.2.1.5.5.2. Market Forecast, 2022 – 2030
9.2.2. Extracellular Proteins; Transmembrane Proteins
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 – 2021
9.2.2.3. Market Forecast, 2022 – 2030
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 – 2021
9.2.2.5.1.2. Market Forecast, 2022 – 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 – 2021
9.2.2.5.2.2. Market Forecast, 2022 – 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 – 2021
9.2.2.5.3.2. Market Forecast, 2022 – 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 – 2021
9.2.2.5.4.2. Market Forecast, 2022 – 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 – 2021
9.2.2.5.5.2. Market Forecast, 2022 – 2030
9.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 – 2021
9.2.3.3. Market Forecast, 2022 – 2030
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2015 – 2021
9.2.3.5.1.2. Market Forecast, 2022 – 2030
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2015 – 2021
9.2.3.5.2.2. Market Forecast, 2022 – 2030
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2015 – 2021
9.2.3.5.3.2. Market Forecast, 2022 – 2030
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2015 – 2021
9.2.3.5.4.2. Market Forecast, 2022 – 2030
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2015 – 2021
9.2.3.5.5.2. Market Forecast, 2022 – 2030
9.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 – 2021
9.2.4.3. Market Forecast, 2022 – 2030
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market Estimation, 2015 – 2021
9.2.4.5.1.2. Market Forecast, 2022 – 2030
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2015 – 2021
9.2.4.5.2.2. Market Forecast, 2022 – 2030
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market Estimation, 2015 – 2021
9.2.4.5.3.2. Market Forecast, 2022 – 2030
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market Estimation, 2015 – 2021
9.2.4.5.4.2. Market Forecast, 2022 – 2030
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market Estimation, 2015 – 2021
9.2.4.5.5.2. Market Forecast, 2022 – 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Potential Targets
10. Global Targeted Protein Degradation Market Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
10.2.1. Breast Cancer
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 – 2021
10.2.1.3. Market Forecast, 2022 – 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 – 2021
10.2.1.5.1.2. Market Forecast, 2022 – 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 – 2021
10.2.1.5.2.2. Market Forecast, 2022 – 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 – 2021
10.2.1.5.3.2. Market Forecast, 2022 – 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 – 2021
10.2.1.5.4.2. Market Forecast, 2022 – 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 – 2021
10.2.1.5.5.2. Market Forecast, 2022 – 2030
10.2.2. Colorectal Cancer
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 – 2021
10.2.2.3. Market Forecast, 2022 – 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 – 2021
10.2.2.5.1.2. Market Forecast, 2022 – 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 – 2021
10.2.2.5.2.2. Market Forecast, 2022 – 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 – 2021
10.2.2.5.3.2. Market Forecast, 2022 – 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 – 2021
10.2.2.5.4.2. Market Forecast, 2022 – 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 – 2021
10.2.2.5.5.2. Market Forecast, 2022 – 2030
10.2.3. Prostate Cancer
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 – 2021
10.2.3.3. Market Forecast, 2022 – 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 – 2021
10.2.3.5.1.2. Market Forecast, 2022 – 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 – 2021
10.2.3.5.2.2. Market Forecast, 2022 – 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 – 2021
10.2.3.5.3.2. Market Forecast, 2022 – 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 – 2021
10.2.3.5.4.2. Market Forecast, 2022 – 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 – 2021
10.2.3.5.5.2. Market Forecast, 2022 – 2030
10.2.4. Alzheimer's disease
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 – 2021
10.2.4.3. Market Forecast, 2022 – 2030
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 – 2021
10.2.4.5.1.2. Market Forecast, 2022 – 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 – 2021
10.2.4.5.2.2. Market Forecast, 2022 – 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 – 2021
10.2.4.5.3.2. Market Forecast, 2022 – 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 – 2021
10.2.4.5.4.2. Market Forecast, 2022 – 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 – 2021
10.2.4.5.5.2. Market Forecast, 2022 – 2030
10.2.5. Liver Fibrosis
10.2.5.1. Definition
10.2.5.2. Market Estimation and Penetration, 2015 – 2021
10.2.5.3. Market Forecast, 2022 – 2030
10.2.5.4. Compound Annual Growth Rate (CAGR)
10.2.5.5. Regional Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 – 2021
10.2.5.5.1.2. Market Forecast, 2022 – 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 – 2021
10.2.5.5.2.2. Market Forecast, 2022 – 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 – 2021
10.2.5.5.3.2. Market Forecast, 2022 – 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 – 2021
10.2.5.5.4.2. Market Forecast, 2022 – 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 – 2021
10.2.5.5.5.2. Market Forecast, 2022 – 2030
10.2.6. Parkinson's disease
10.2.6.1. Definition
10.2.6.2. Market Estimation and Penetration, 2015 – 2021
10.2.6.3. Market Forecast, 2022 – 2030
10.2.6.4. Compound Annual Growth Rate (CAGR)
10.2.6.5. Regional Bifurcation
10.2.6.5.1. North America
10.2.6.5.1.1. Market Estimation, 2015 – 2021
10.2.6.5.1.2. Market Forecast, 2022 – 2030
10.2.6.5.2. Europe
10.2.6.5.2.1. Market Estimation, 2015 – 2021
10.2.6.5.2.2. Market Forecast, 2022 – 2030
10.2.6.5.3. Asia Pacific
10.2.6.5.3.1. Market Estimation, 2015 – 2021
10.2.6.5.3.2. Market Forecast, 2022 – 2030
10.2.6.5.4. Middle East and Africa
10.2.6.5.4.1. Market Estimation, 2015 – 2021
10.2.6.5.4.2. Market Forecast, 2022 – 2030
10.2.6.5.5. Latin America
10.2.6.5.5.1. Market Estimation, 2015 – 2021
10.2.6.5.5.2. Market Forecast, 2022 – 2030
10.2.7. Psoriasis
10.2.7.1. Definition
10.2.7.2. Market Estimation and Penetration, 2015 – 2021
10.2.7.3. Market Forecast, 2022 – 2030
10.2.7.4. Compound Annual Growth Rate (CAGR)
10.2.7.5. Regional Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market Estimation, 2015 – 2021
10.2.7.5.1.2. Market Forecast, 2022 – 2030
10.2.7.5.2. Europe
10.2.7.5.2.1. Market Estimation, 2015 – 2021
10.2.7.5.2.2. Market Forecast, 2022 – 2030
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market Estimation, 2015 – 2021
10.2.7.5.3.2. Market Forecast, 2022 – 2030
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market Estimation, 2015 – 2021
10.2.7.5.4.2. Market Forecast, 2022 – 2030
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market Estimation, 2015 – 2021
10.2.7.5.5.2. Market Forecast, 2022 – 2030
10.2.8. Rheumatoid Arthritis
10.2.8.1. Definition
10.2.8.2. Market Estimation and Penetration, 2015 – 2021
10.2.8.3. Market Forecast, 2022 – 2030
10.2.8.4. Compound Annual Growth Rate (CAGR)
10.2.8.5. Regional Bifurcation
10.2.8.5.1. North America
10.2.8.5.1.1. Market Estimation, 2015 – 2021
10.2.8.5.1.2. Market Forecast, 2022 – 2030
10.2.8.5.2. Europe
10.2.8.5.2.1. Market Estimation, 2015 – 2021
10.2.8.5.2.2. Market Forecast, 2022 – 2030
10.2.8.5.3. Asia Pacific
10.2.8.5.3.1. Market Estimation, 2015 – 2021
10.2.8.5.3.2. Market Forecast, 2022 – 2030
10.2.8.5.4. Middle East and Africa
10.2.8.5.4.1. Market Estimation, 2015 – 2021
10.2.8.5.4.2. Market Forecast, 2022 – 2030
10.2.8.5.5. Latin America
10.2.8.5.5.1. Market Estimation, 2015 – 2021
10.2.8.5.5.2. Market Forecast, 2022 – 2030
10.2.9. Autoimmune Diseases
10.2.9.1. Definition
10.2.9.2. Market Estimation and Penetration, 2015 – 2021
10.2.9.3. Market Forecast, 2022 – 2030
10.2.9.4. Compound Annual Growth Rate (CAGR)
10.2.9.5. Regional Bifurcation
10.2.9.5.1. North America
10.2.9.5.1.1. Market Estimation, 2015 – 2021
10.2.9.5.1.2. Market Forecast, 2022 – 2030
10.2.9.5.2. Europe
10.2.9.5.2.1. Market Estimation, 2015 – 2021
10.2.9.5.2.2. Market Forecast, 2022 – 2030
10.2.9.5.3. Asia Pacific
10.2.9.5.3.1. Market Estimation, 2015 – 2021
10.2.9.5.3.2. Market Forecast, 2022 – 2030
10.2.9.5.4. Middle East and Africa
10.2.9.5.4.1. Market Estimation, 2015 – 2021
10.2.9.5.4.2. Market Forecast, 2022 – 2030
10.2.9.5.5. Latin America
10.2.9.5.5.1. Market Estimation, 2015 – 2021
10.2.9.5.5.2. Market Forecast, 2022 – 2030
10.2.10. Others
10.2.10.1. Definition
10.2.10.2. Market Estimation and Penetration, 2015 – 2021
10.2.10.3. Market Forecast, 2022 – 2030
10.2.10.4. Compound Annual Growth Rate (CAGR)
10.2.10.5. Regional Bifurcation
10.2.10.5.1. North America
10.2.10.5.1.1. Market Estimation, 2015 – 2021
10.2.10.5.1.2. Market Forecast, 2022 – 2030
10.2.10.5.2. Europe
10.2.10.5.2.1. Market Estimation, 2015 – 2021
10.2.10.5.2.2. Market Forecast, 2022 – 2030
10.2.10.5.3. Asia Pacific
10.2.10.5.3.1. Market Estimation, 2015 – 2021
10.2.10.5.3.2. Market Forecast, 2022 – 2030
10.2.10.5.4. Middle East and Africa
10.2.10.5.4.1. Market Estimation, 2015 – 2021
10.2.10.5.4.2. Market Forecast, 2022 – 2030
10.2.10.5.5. Latin America
10.2.10.5.5.1. Market Estimation, 2015 – 2021
10.2.10.5.5.2. Market Forecast, 2022 – 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Type of Diseases
11. North America Targeted Protein Degradation Market Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North America Targeted Protein Degradation Market Revenue (US$ Mn)
11.2. North America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
11.2.1. Active Degraders (PROTACs)
11.2.2. LYTAC (Lysosome Targeting Chimera) Technology
11.2.3. Autophagosome-tethering Compound (ATTEC)
11.2.4. Autophagy-targeting Chimera (AUTAC) System
11.2.5. TAG Degradation Platform (aTAG, dTAG)
11.2.6. Degrader Building Blocks
11.2.7. Ubiquitin Proteasome System Proteins and Assays
11.2.8. Assays for Protein Degradation
11.2.9. Custom Degrader Services
11.2.10. SARDs and SERDs
11.2.11. Others
11.3. North America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
11.3.1. Intracellular Proteins
11.3.2. Extracellular Proteins; Transmembrane Proteins
11.3.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
11.3.4. Intracellular Proteins; Non-protein Autophagy Substrates
11.4. North America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
11.4.1. Breast Cancer
11.4.2. Colorectal Cancer
11.4.3. Prostate Cancer
11.4.4. Alzheimer's disease
11.4.5. Liver Fibrosis
11.4.6. Parkinson's disease
11.4.7. Psoriasis
11.4.8. Rheumatoid Arthritis
11.4.9. Autoimmune Diseases
11.4.10. Others
11.5. North America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.1.1.1. Active Degraders (PROTACs)
11.5.1.1.2. LYTAC (Lysosome Targeting Chimera) Technology
11.5.1.1.3. Autophagosome-tethering Compound (ATTEC)
11.5.1.1.4. Autophagy-targeting Chimera (AUTAC) System
11.5.1.1.5. TAG Degradation Platform (aTAG, dTAG)
11.5.1.1.6. Degrader Building Blocks
11.5.1.1.7. Ubiquitin Proteasome System Proteins and Assays
11.5.1.1.8. Assays for Protein Degradation
11.5.1.1.9. Custom Degrader Services
11.5.1.1.10. SARDs and SERDs
11.5.1.1.11. Others
11.5.1.2. U.S Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
11.5.1.2.1. Intracellular Proteins
11.5.1.2.2. Extracellular Proteins; Transmembrane Proteins
11.5.1.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
11.5.1.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
11.5.1.3. U.S Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
11.5.1.3.1. Breast Cancer
11.5.1.3.2. Colorectal Cancer
11.5.1.3.3. Prostate Cancer
11.5.1.3.4. Alzheimer's disease
11.5.1.3.5. Liver Fibrosis
11.5.1.3.6. Parkinson's disease
11.5.1.3.7. Psoriasis
11.5.1.3.8. Rheumatoid Arthritis
11.5.1.3.9. Autoimmune Diseases
11.5.1.3.10. Others
11.5.2. Canada
11.5.2.1. Canada Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.2.1.1. Active Degraders (PROTACs)
11.5.2.1.2. LYTAC (Lysosome Targeting Chimera) Technology
11.5.2.1.3. Autophagosome-tethering Compound (ATTEC)
11.5.2.1.4. Autophagy-targeting Chimera (AUTAC) System
11.5.2.1.5. TAG Degradation Platform (aTAG, dTAG)
11.5.2.1.6. Degrader Building Blocks
11.5.2.1.7. Ubiquitin Proteasome System Proteins and Assays
11.5.2.1.8. Assays for Protein Degradation
11.5.2.1.9. Custom Degrader Services
11.5.2.1.10. SARDs and SERDs
11.5.2.1.11. Others
11.5.2.2. Canada Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
11.5.2.2.1. Intracellular Proteins
11.5.2.2.2. Extracellular Proteins; Transmembrane Proteins
11.5.2.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
11.5.2.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
11.5.2.3. Canada Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
11.5.2.3.1. Breast Cancer
11.5.2.3.2. Colorectal Cancer
11.5.2.3.3. Prostate Cancer
11.5.2.3.4. Alzheimer's disease
11.5.2.3.5. Liver Fibrosis
11.5.2.3.6. Parkinson's disease
11.5.2.3.7. Psoriasis
11.5.2.3.8. Rheumatoid Arthritis
11.5.2.3.9. Autoimmune Diseases
11.5.2.3.10. Others
11.5.3. Mexico
11.5.3.1. Mexico Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.3.1.1. Active Degraders (PROTACs)
11.5.3.1.2. LYTAC (Lysosome Targeting Chimera) Technology
11.5.3.1.3. Autophagosome-tethering Compound (ATTEC)
11.5.3.1.4. Autophagy-targeting Chimera (AUTAC) System
11.5.3.1.5. TAG Degradation Platform (aTAG, dTAG)
11.5.3.1.6. Degrader Building Blocks
11.5.3.1.7. Ubiquitin Proteasome System Proteins and Assays
11.5.3.1.8. Assays for Protein Degradation
11.5.3.1.9. Custom Degrader Services
11.5.3.1.10. SARDs and SERDs
11.5.3.1.11. Others
11.5.3.2. Mexico Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
11.5.3.2.1. Intracellular Proteins
11.5.3.2.2. Extracellular Proteins; Transmembrane Proteins
11.5.3.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
11.5.3.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
11.5.3.3. Mexico Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
11.5.3.3.1. Breast Cancer
11.5.3.3.2. Colorectal Cancer
11.5.3.3.3. Prostate Cancer
11.5.3.3.4. Alzheimer's disease
11.5.3.3.5. Liver Fibrosis
11.5.3.3.6. Parkinson's disease
11.5.3.3.7. Psoriasis
11.5.3.3.8. Rheumatoid Arthritis
11.5.3.3.9. Autoimmune Diseases
11.5.3.3.10. Others
11.5.4. Rest of North America
11.5.4.1. Rest of North America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.4.1.1. Active Degraders (PROTACs)
11.5.4.1.2. LYTAC (Lysosome Targeting Chimera) Technology
11.5.4.1.3. Autophagosome-tethering Compound (ATTEC)
11.5.4.1.4. Autophagy-targeting Chimera (AUTAC) System
11.5.4.1.5. TAG Degradation Platform (aTAG, dTAG)
11.5.4.1.6. Degrader Building Blocks
11.5.4.1.7. Ubiquitin Proteasome System Proteins and Assays
11.5.4.1.8. Assays for Protein Degradation
11.5.4.1.9. Custom Degrader Services
11.5.4.1.10. SARDs and SERDs
11.5.4.1.11. Others
11.5.4.2. Rest of North America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
11.5.4.2.1. Intracellular Proteins
11.5.4.2.2. Extracellular Proteins; Transmembrane Proteins
11.5.4.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
11.5.4.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
11.5.4.3. Rest of North America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
11.5.4.3.1. Breast Cancer
11.5.4.3.2. Colorectal Cancer
11.5.4.3.3. Prostate Cancer
11.5.4.3.4. Alzheimer's disease
11.5.4.3.5. Liver Fibrosis
11.5.4.3.6. Parkinson's disease
11.5.4.3.7. Psoriasis
11.5.4.3.8. Rheumatoid Arthritis
11.5.4.3.9. Autoimmune Diseases
11.5.4.3.10. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Offering
11.6.3. By Potential Targets
11.6.4. By Type of Diseases
12. Europe Targeted Protein Degradation Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe Targeted Protein Degradation Market Revenue (US$ Mn)
12.2. Europe Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.2.1. Active Degraders (PROTACs)
12.2.2. LYTAC (Lysosome Targeting Chimera) Technology
12.2.3. Autophagosome-tethering Compound (ATTEC)
12.2.4. Autophagy-targeting Chimera (AUTAC) System
12.2.5. TAG Degradation Platform (aTAG, dTAG)
12.2.6. Degrader Building Blocks
12.2.7. Ubiquitin Proteasome System Proteins and Assays
12.2.8. Assays for Protein Degradation
12.2.9. Custom Degrader Services
12.2.10. SARDs and SERDs
12.2.11. Others
12.3. Europe Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.3.1. Intracellular Proteins
12.3.2. Extracellular Proteins; Transmembrane Proteins
12.3.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.3.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.4. Europe Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.4.1. Breast Cancer
12.4.2. Colorectal Cancer
12.4.3. Prostate Cancer
12.4.4. Alzheimer's disease
12.4.5. Liver Fibrosis
12.4.6. Parkinson's disease
12.4.7. Psoriasis
12.4.8. Rheumatoid Arthritis
12.4.9. Autoimmune Diseases
12.4.10. Others
12.5. Europe Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.1.1.1. Active Degraders (PROTACs)
12.5.1.1.2. LYTAC (Lysosome Targeting Chimera) Technology
12.5.1.1.3. Autophagosome-tethering Compound (ATTEC)
12.5.1.1.4. Autophagy-targeting Chimera (AUTAC) System
12.5.1.1.5. TAG Degradation Platform (aTAG, dTAG)
12.5.1.1.6. Degrader Building Blocks
12.5.1.1.7. Ubiquitin Proteasome System Proteins and Assays
12.5.1.1.8. Assays for Protein Degradation
12.5.1.1.9. Custom Degrader Services
12.5.1.1.10. SARDs and SERDs
12.5.1.1.11. Others
12.5.1.2. France Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.5.1.2.1. Intracellular Proteins
12.5.1.2.2. Extracellular Proteins; Transmembrane Proteins
12.5.1.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.5.1.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.5.1.3. France Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.5.1.3.1. Breast Cancer
12.5.1.3.2. Colorectal Cancer
12.5.1.3.3. Prostate Cancer
12.5.1.3.4. Alzheimer's disease
12.5.1.3.5. Liver Fibrosis
12.5.1.3.6. Parkinson's disease
12.5.1.3.7. Psoriasis
12.5.1.3.8. Rheumatoid Arthritis
12.5.1.3.9. Autoimmune Diseases
12.5.1.3.10. Others
12.5.2. The UK
12.5.2.1. The UK Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.2.1.1. Active Degraders (PROTACs)
12.5.2.1.2. LYTAC (Lysosome Targeting Chimera) Technology
12.5.2.1.3. Autophagosome-tethering Compound (ATTEC)
12.5.2.1.4. Autophagy-targeting Chimera (AUTAC) System
12.5.2.1.5. TAG Degradation Platform (aTAG, dTAG)
12.5.2.1.6. Degrader Building Blocks
12.5.2.1.7. Ubiquitin Proteasome System Proteins and Assays
12.5.2.1.8. Assays for Protein Degradation
12.5.2.1.9. Custom Degrader Services
12.5.2.1.10. SARDs and SERDs
12.5.2.1.11. Others
12.5.2.2. The UK Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.5.2.2.1. Intracellular Proteins
12.5.2.2.2. Extracellular Proteins; Transmembrane Proteins
12.5.2.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.5.2.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.5.2.3. The UK Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.5.2.3.1. Breast Cancer
12.5.2.3.2. Colorectal Cancer
12.5.2.3.3. Prostate Cancer
12.5.2.3.4. Alzheimer's disease
12.5.2.3.5. Liver Fibrosis
12.5.2.3.6. Parkinson's disease
12.5.2.3.7. Psoriasis
12.5.2.3.8. Rheumatoid Arthritis
12.5.2.3.9. Autoimmune Diseases
12.5.2.3.10. Others
12.5.3. Spain
12.5.3.1. Spain Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.3.1.1. Active Degraders (PROTACs)
12.5.3.1.2. LYTAC (Lysosome Targeting Chimera) Technology
12.5.3.1.3. Autophagosome-tethering Compound (ATTEC)
12.5.3.1.4. Autophagy-targeting Chimera (AUTAC) System
12.5.3.1.5. TAG Degradation Platform (aTAG, dTAG)
12.5.3.1.6. Degrader Building Blocks
12.5.3.1.7. Ubiquitin Proteasome System Proteins and Assays
12.5.3.1.8. Assays for Protein Degradation
12.5.3.1.9. Custom Degrader Services
12.5.3.1.10. SARDs and SERDs
12.5.3.1.11. Others
12.5.3.2. Spain Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.5.3.2.1. Intracellular Proteins
12.5.3.2.2. Extracellular Proteins; Transmembrane Proteins
12.5.3.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.5.3.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.5.3.3. Spain Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.5.3.3.1. Breast Cancer
12.5.3.3.2. Colorectal Cancer
12.5.3.3.3. Prostate Cancer
12.5.3.3.4. Alzheimer's disease
12.5.3.3.5. Liver Fibrosis
12.5.3.3.6. Parkinson's disease
12.5.3.3.7. Psoriasis
12.5.3.3.8. Rheumatoid Arthritis
12.5.3.3.9. Autoimmune Diseases
12.5.3.3.10. Others
12.5.4. Germany
12.5.4.1. Germany Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.4.1.1. Active Degraders (PROTACs)
12.5.4.1.2. LYTAC (Lysosome Targeting Chimera) Technology
12.5.4.1.3. Autophagosome-tethering Compound (ATTEC)
12.5.4.1.4. Autophagy-targeting Chimera (AUTAC) System
12.5.4.1.5. TAG Degradation Platform (aTAG, dTAG)
12.5.4.1.6. Degrader Building Blocks
12.5.4.1.7. Ubiquitin Proteasome System Proteins and Assays
12.5.4.1.8. Assays for Protein Degradation
12.5.4.1.9. Custom Degrader Services
12.5.4.1.10. SARDs and SERDs
12.5.4.1.11. Others
12.5.4.2. Germany Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.5.4.2.1. Intracellular Proteins
12.5.4.2.2. Extracellular Proteins; Transmembrane Proteins
12.5.4.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.5.4.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.5.4.3. Germany Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.5.4.3.1. Breast Cancer
12.5.4.3.2. Colorectal Cancer
12.5.4.3.3. Prostate Cancer
12.5.4.3.4. Alzheimer's disease
12.5.4.3.5. Liver Fibrosis
12.5.4.3.6. Parkinson's disease
12.5.4.3.7. Psoriasis
12.5.4.3.8. Rheumatoid Arthritis
12.5.4.3.9. Autoimmune Diseases
12.5.4.3.10. Others
12.5.5. Italy
12.5.5.1. Italy Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.5.1.1. Active Degraders (PROTACs)
12.5.5.1.2. LYTAC (Lysosome Targeting Chimera) Technology
12.5.5.1.3. Autophagosome-tethering Compound (ATTEC)
12.5.5.1.4. Autophagy-targeting Chimera (AUTAC) System
12.5.5.1.5. TAG Degradation Platform (aTAG, dTAG)
12.5.5.1.6. Degrader Building Blocks
12.5.5.1.7. Ubiquitin Proteasome System Proteins and Assays
12.5.5.1.8. Assays for Protein Degradation
12.5.5.1.9. Custom Degrader Services
12.5.5.1.10. SARDs and SERDs
12.5.5.1.11. Others
12.5.5.2. Italy Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.5.5.2.1. Intracellular Proteins
12.5.5.2.2. Extracellular Proteins; Transmembrane Proteins
12.5.5.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.5.5.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.5.5.3. Italy Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.5.5.3.1. Breast Cancer
12.5.5.3.2. Colorectal Cancer
12.5.5.3.3. Prostate Cancer
12.5.5.3.4. Alzheimer's disease
12.5.5.3.5. Liver Fibrosis
12.5.5.3.6. Parkinson's disease
12.5.5.3.7. Psoriasis
12.5.5.3.8. Rheumatoid Arthritis
12.5.5.3.9. Autoimmune Diseases
12.5.5.3.10. Others
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.6.1.1. Active Degraders (PROTACs)
12.5.6.1.2. LYTAC (Lysosome Targeting Chimera) Technology
12.5.6.1.3. Autophagosome-tethering Compound (ATTEC)
12.5.6.1.4. Autophagy-targeting Chimera (AUTAC) System
12.5.6.1.5. TAG Degradation Platform (aTAG, dTAG)
12.5.6.1.6. Degrader Building Blocks
12.5.6.1.7. Ubiquitin Proteasome System Proteins and Assays
12.5.6.1.8. Assays for Protein Degradation
12.5.6.1.9. Custom Degrader Services
12.5.6.1.10. SARDs and SERDs
12.5.6.1.11. Others
12.5.6.2. Nordic Countries Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.5.6.2.1. Intracellular Proteins
12.5.6.2.2. Extracellular Proteins; Transmembrane Proteins
12.5.6.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.5.6.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.5.6.3. Nordic Countries Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.5.6.3.1. Breast Cancer
12.5.6.3.2. Colorectal Cancer
12.5.6.3.3. Prostate Cancer
12.5.6.3.4. Alzheimer's disease
12.5.6.3.5. Liver Fibrosis
12.5.6.3.6. Parkinson's disease
12.5.6.3.7. Psoriasis
12.5.6.3.8. Rheumatoid Arthritis
12.5.6.3.9. Autoimmune Diseases
12.5.6.3.10. Others
12.5.6.4. Nordic Countries Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.7.1.1. Active Degraders (PROTACs)
12.5.7.1.2. LYTAC (Lysosome Targeting Chimera) Technology
12.5.7.1.3. Autophagosome-tethering Compound (ATTEC)
12.5.7.1.4. Autophagy-targeting Chimera (AUTAC) System
12.5.7.1.5. TAG Degradation Platform (aTAG, dTAG)
12.5.7.1.6. Degrader Building Blocks
12.5.7.1.7. Ubiquitin Proteasome System Proteins and Assays
12.5.7.1.8. Assays for Protein Degradation
12.5.7.1.9. Custom Degrader Services
12.5.7.1.10. SARDs and SERDs
12.5.7.1.11. Others
12.5.7.2. Benelux Union Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.5.7.2.1. Intracellular Proteins
12.5.7.2.2. Extracellular Proteins; Transmembrane Proteins
12.5.7.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.5.7.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.5.7.3. Benelux Union Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.5.7.3.1. Breast Cancer
12.5.7.3.2. Colorectal Cancer
12.5.7.3.3. Prostate Cancer
12.5.7.3.4. Alzheimer's disease
12.5.7.3.5. Liver Fibrosis
12.5.7.3.6. Parkinson's disease
12.5.7.3.7. Psoriasis
12.5.7.3.8. Rheumatoid Arthritis
12.5.7.3.9. Autoimmune Diseases
12.5.7.3.10. Others
12.5.7.4. Benelux Union Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.8.1.1. Active Degraders (PROTACs)
12.5.8.1.2. LYTAC (Lysosome Targeting Chimera) Technology
12.5.8.1.3. Autophagosome-tethering Compound (ATTEC)
12.5.8.1.4. Autophagy-targeting Chimera (AUTAC) System
12.5.8.1.5. TAG Degradation Platform (aTAG, dTAG)
12.5.8.1.6. Degrader Building Blocks
12.5.8.1.7. Ubiquitin Proteasome System Proteins and Assays
12.5.8.1.8. Assays for Protein Degradation
12.5.8.1.9. Custom Degrader Services
12.5.8.1.10. SARDs and SERDs
12.5.8.1.11. Others
12.5.8.2. Rest of Europe Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
12.5.8.2.1. Intracellular Proteins
12.5.8.2.2. Extracellular Proteins; Transmembrane Proteins
12.5.8.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
12.5.8.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
12.5.8.3. Rest of Europe Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
12.5.8.3.1. Breast Cancer
12.5.8.3.2. Colorectal Cancer
12.5.8.3.3. Prostate Cancer
12.5.8.3.4. Alzheimer's disease
12.5.8.3.5. Liver Fibrosis
12.5.8.3.6. Parkinson's disease
12.5.8.3.7. Psoriasis
12.5.8.3.8. Rheumatoid Arthritis
12.5.8.3.9. Autoimmune Diseases
12.5.8.3.10. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Offering
12.6.3. By Potential Targets
12.6.4. By Type of Diseases
13. Asia Pacific Targeted Protein Degradation Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia Pacific Targeted Protein Degradation Market Revenue (US$ Mn)
13.2. Asia Pacific Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.2.1. Active Degraders (PROTACs)
13.2.2. LYTAC (Lysosome Targeting Chimera) Technology
13.2.3. Autophagosome-tethering Compound (ATTEC)
13.2.4. Autophagy-targeting Chimera (AUTAC) System
13.2.5. TAG Degradation Platform (aTAG, dTAG)
13.2.6. Degrader Building Blocks
13.2.7. Ubiquitin Proteasome System Proteins and Assays
13.2.8. Assays for Protein Degradation
13.2.9. Custom Degrader Services
13.2.10. SARDs and SERDs
13.2.11. Others
13.3. Asia Pacific Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.3.1. Intracellular Proteins
13.3.2. Extracellular Proteins; Transmembrane Proteins
13.3.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.3.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.4. Asia Pacific Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.4.1. Breast Cancer
13.4.2. Colorectal Cancer
13.4.3. Prostate Cancer
13.4.4. Alzheimer's disease
13.4.5. Liver Fibrosis
13.4.6. Parkinson's disease
13.4.7. Psoriasis
13.4.8. Rheumatoid Arthritis
13.4.9. Autoimmune Diseases
13.4.10. Others
13.5. Asia Pacific Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.1.1.1. Active Degraders (PROTACs)
13.5.1.1.2. LYTAC (Lysosome Targeting Chimera) Technology
13.5.1.1.3. Autophagosome-tethering Compound (ATTEC)
13.5.1.1.4. Autophagy-targeting Chimera (AUTAC) System
13.5.1.1.5. TAG Degradation Platform (aTAG, dTAG)
13.5.1.1.6. Degrader Building Blocks
13.5.1.1.7. Ubiquitin Proteasome System Proteins and Assays
13.5.1.1.8. Assays for Protein Degradation
13.5.1.1.9. Custom Degrader Services
13.5.1.1.10. SARDs and SERDs
13.5.1.1.11. Others
13.5.1.2. China Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.5.1.2.1. Intracellular Proteins
13.5.1.2.2. Extracellular Proteins; Transmembrane Proteins
13.5.1.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.5.1.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.5.1.3. China Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.5.1.3.1. Breast Cancer
13.5.1.3.2. Colorectal Cancer
13.5.1.3.3. Prostate Cancer
13.5.1.3.4. Alzheimer's disease
13.5.1.3.5. Liver Fibrosis
13.5.1.3.6. Parkinson's disease
13.5.1.3.7. Psoriasis
13.5.1.3.8. Rheumatoid Arthritis
13.5.1.3.9. Autoimmune Diseases
13.5.1.3.10. Others
13.5.2. Japan
13.5.2.1. Japan Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.2.1.1. Active Degraders (PROTACs)
13.5.2.1.2. LYTAC (Lysosome Targeting Chimera) Technology
13.5.2.1.3. Autophagosome-tethering Compound (ATTEC)
13.5.2.1.4. Autophagy-targeting Chimera (AUTAC) System
13.5.2.1.5. TAG Degradation Platform (aTAG, dTAG)
13.5.2.1.6. Degrader Building Blocks
13.5.2.1.7. Ubiquitin Proteasome System Proteins and Assays
13.5.2.1.8. Assays for Protein Degradation
13.5.2.1.9. Custom Degrader Services
13.5.2.1.10. SARDs and SERDs
13.5.2.1.11. Others
13.5.2.2. Japan Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.5.2.2.1. Intracellular Proteins
13.5.2.2.2. Extracellular Proteins; Transmembrane Proteins
13.5.2.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.5.2.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.5.2.3. Japan Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.5.2.3.1. Breast Cancer
13.5.2.3.2. Colorectal Cancer
13.5.2.3.3. Prostate Cancer
13.5.2.3.4. Alzheimer's disease
13.5.2.3.5. Liver Fibrosis
13.5.2.3.6. Parkinson's disease
13.5.2.3.7. Psoriasis
13.5.2.3.8. Rheumatoid Arthritis
13.5.2.3.9. Autoimmune Diseases
13.5.2.3.10. Others
13.5.3. India
13.5.3.1. India Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.3.1.1. Active Degraders (PROTACs)
13.5.3.1.2. LYTAC (Lysosome Targeting Chimera) Technology
13.5.3.1.3. Autophagosome-tethering Compound (ATTEC)
13.5.3.1.4. Autophagy-targeting Chimera (AUTAC) System
13.5.3.1.5. TAG Degradation Platform (aTAG, dTAG)
13.5.3.1.6. Degrader Building Blocks
13.5.3.1.7. Ubiquitin Proteasome System Proteins and Assays
13.5.3.1.8. Assays for Protein Degradation
13.5.3.1.9. Custom Degrader Services
13.5.3.1.10. SARDs and SERDs
13.5.3.1.11. Others
13.5.3.2. India Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.5.3.2.1. Intracellular Proteins
13.5.3.2.2. Extracellular Proteins; Transmembrane Proteins
13.5.3.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.5.3.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.5.3.3. India Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.5.3.3.1. Breast Cancer
13.5.3.3.2. Colorectal Cancer
13.5.3.3.3. Prostate Cancer
13.5.3.3.4. Alzheimer's disease
13.5.3.3.5. Liver Fibrosis
13.5.3.3.6. Parkinson's disease
13.5.3.3.7. Psoriasis
13.5.3.3.8. Rheumatoid Arthritis
13.5.3.3.9. Autoimmune Diseases
13.5.3.3.10. Others
13.5.4. New Zealand
13.5.4.1. New Zealand Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.4.1.1. Active Degraders (PROTACs)
13.5.4.1.2. LYTAC (Lysosome Targeting Chimera) Technology
13.5.4.1.3. Autophagosome-tethering Compound (ATTEC)
13.5.4.1.4. Autophagy-targeting Chimera (AUTAC) System
13.5.4.1.5. TAG Degradation Platform (aTAG, dTAG)
13.5.4.1.6. Degrader Building Blocks
13.5.4.1.7. Ubiquitin Proteasome System Proteins and Assays
13.5.4.1.8. Assays for Protein Degradation
13.5.4.1.9. Custom Degrader Services
13.5.4.1.10. SARDs and SERDs
13.5.4.1.11. Others
13.5.4.2. New Zealand Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.5.4.2.1. Intracellular Proteins
13.5.4.2.2. Extracellular Proteins; Transmembrane Proteins
13.5.4.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.5.4.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.5.4.3. New Zealand Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.5.4.3.1. Breast Cancer
13.5.4.3.2. Colorectal Cancer
13.5.4.3.3. Prostate Cancer
13.5.4.3.4. Alzheimer's disease
13.5.4.3.5. Liver Fibrosis
13.5.4.3.6. Parkinson's disease
13.5.4.3.7. Psoriasis
13.5.4.3.8. Rheumatoid Arthritis
13.5.4.3.9. Autoimmune Diseases
13.5.4.3.10. Others
13.5.5. Australia
13.5.5.1. Australia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.5.1.1. Active Degraders (PROTACs)
13.5.5.1.2. LYTAC (Lysosome Targeting Chimera) Technology
13.5.5.1.3. Autophagosome-tethering Compound (ATTEC)
13.5.5.1.4. Autophagy-targeting Chimera (AUTAC) System
13.5.5.1.5. TAG Degradation Platform (aTAG, dTAG)
13.5.5.1.6. Degrader Building Blocks
13.5.5.1.7. Ubiquitin Proteasome System Proteins and Assays
13.5.5.1.8. Assays for Protein Degradation
13.5.5.1.9. Custom Degrader Services
13.5.5.1.10. SARDs and SERDs
13.5.5.1.11. Others
13.5.5.2. Australia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.5.5.2.1. Intracellular Proteins
13.5.5.2.2. Extracellular Proteins; Transmembrane Proteins
13.5.5.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.5.5.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.5.5.3. Australia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.5.5.3.1. Breast Cancer
13.5.5.3.2. Colorectal Cancer
13.5.5.3.3. Prostate Cancer
13.5.5.3.4. Alzheimer's disease
13.5.5.3.5. Liver Fibrosis
13.5.5.3.6. Parkinson's disease
13.5.5.3.7. Psoriasis
13.5.5.3.8. Rheumatoid Arthritis
13.5.5.3.9. Autoimmune Diseases
13.5.5.3.10. Others
13.5.6. South Korea
13.5.6.1. South Korea Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.6.1.1. Active Degraders (PROTACs)
13.5.6.1.2. LYTAC (Lysosome Targeting Chimera) Technology
13.5.6.1.3. Autophagosome-tethering Compound (ATTEC)
13.5.6.1.4. Autophagy-targeting Chimera (AUTAC) System
13.5.6.1.5. TAG Degradation Platform (aTAG, dTAG)
13.5.6.1.6. Degrader Building Blocks
13.5.6.1.7. Ubiquitin Proteasome System Proteins and Assays
13.5.6.1.8. Assays for Protein Degradation
13.5.6.1.9. Custom Degrader Services
13.5.6.1.10. SARDs and SERDs
13.5.6.1.11. Others
13.5.6.2. South Korea Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.5.6.2.1. Intracellular Proteins
13.5.6.2.2. Extracellular Proteins; Transmembrane Proteins
13.5.6.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.5.6.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.5.6.3. South Korea Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.5.6.3.1. Breast Cancer
13.5.6.3.2. Colorectal Cancer
13.5.6.3.3. Prostate Cancer
13.5.6.3.4. Alzheimer's disease
13.5.6.3.5. Liver Fibrosis
13.5.6.3.6. Parkinson's disease
13.5.6.3.7. Psoriasis
13.5.6.3.8. Rheumatoid Arthritis
13.5.6.3.9. Autoimmune Diseases
13.5.6.3.10. Others
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.7.1.1. Active Degraders (PROTACs)
13.5.7.1.2. LYTAC (Lysosome Targeting Chimera) Technology
13.5.7.1.3. Autophagosome-tethering Compound (ATTEC)
13.5.7.1.4. Autophagy-targeting Chimera (AUTAC) System
13.5.7.1.5. TAG Degradation Platform (aTAG, dTAG)
13.5.7.1.6. Degrader Building Blocks
13.5.7.1.7. Ubiquitin Proteasome System Proteins and Assays
13.5.7.1.8. Assays for Protein Degradation
13.5.7.1.9. Custom Degrader Services
13.5.7.1.10. SARDs and SERDs
13.5.7.1.11. Others
13.5.7.2. Southeast Asia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.5.7.2.1. Intracellular Proteins
13.5.7.2.2. Extracellular Proteins; Transmembrane Proteins
13.5.7.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.5.7.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.5.7.3. Southeast Asia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.5.7.3.1. Breast Cancer
13.5.7.3.2. Colorectal Cancer
13.5.7.3.3. Prostate Cancer
13.5.7.3.4. Alzheimer's disease
13.5.7.3.5. Liver Fibrosis
13.5.7.3.6. Parkinson's disease
13.5.7.3.7. Psoriasis
13.5.7.3.8. Rheumatoid Arthritis
13.5.7.3.9. Autoimmune Diseases
13.5.7.3.10. Others
13.5.7.4. Southeast Asia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.8.1.1. Active Degraders (PROTACs)
13.5.8.1.2. LYTAC (Lysosome Targeting Chimera) Technology
13.5.8.1.3. Autophagosome-tethering Compound (ATTEC)
13.5.8.1.4. Autophagy-targeting Chimera (AUTAC) System
13.5.8.1.5. TAG Degradation Platform (aTAG, dTAG)
13.5.8.1.6. Degrader Building Blocks
13.5.8.1.7. Ubiquitin Proteasome System Proteins and Assays
13.5.8.1.8. Assays for Protein Degradation
13.5.8.1.9. Custom Degrader Services
13.5.8.1.10. SARDs and SERDs
13.5.8.1.11. Others
13.5.8.2. Rest of Asia Pacific Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
13.5.8.2.1. Intracellular Proteins
13.5.8.2.2. Extracellular Proteins; Transmembrane Proteins
13.5.8.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
13.5.8.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
13.5.8.3. Rest of Asia Pacific Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
13.5.8.3.1. Breast Cancer
13.5.8.3.2. Colorectal Cancer
13.5.8.3.3. Prostate Cancer
13.5.8.3.4. Alzheimer's disease
13.5.8.3.5. Liver Fibrosis
13.5.8.3.6. Parkinson's disease
13.5.8.3.7. Psoriasis
13.5.8.3.8. Rheumatoid Arthritis
13.5.8.3.9. Autoimmune Diseases
13.5.8.3.10. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Offering
13.6.3. By Potential Targets
13.6.4. By Type of Diseases
14. Middle East and Africa Targeted Protein Degradation Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle East and Africa Targeted Protein Degradation Market Revenue (US$ Mn)
14.2. Middle East and Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
14.2.1. Active Degraders (PROTACs)
14.2.2. LYTAC (Lysosome Targeting Chimera) Technology
14.2.3. Autophagosome-tethering Compound (ATTEC)
14.2.4. Autophagy-targeting Chimera (AUTAC) System
14.2.5. TAG Degradation Platform (aTAG, dTAG)
14.2.6. Degrader Building Blocks
14.2.7. Ubiquitin Proteasome System Proteins and Assays
14.2.8. Assays for Protein Degradation
14.2.9. Custom Degrader Services
14.2.10. SARDs and SERDs
14.2.11. Others
14.3. Middle East and Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
14.3.1. Intracellular Proteins
14.3.2. Extracellular Proteins; Transmembrane Proteins
14.3.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
14.3.4. Intracellular Proteins; Non-protein Autophagy Substrates
14.4. Middle East and Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
14.4.1. Breast Cancer
14.4.2. Colorectal Cancer
14.4.3. Prostate Cancer
14.4.4. Alzheimer's disease
14.4.5. Liver Fibrosis
14.4.6. Parkinson's disease
14.4.7. Psoriasis
14.4.8. Rheumatoid Arthritis
14.4.9. Autoimmune Diseases
14.4.10. Others
14.5. Middle East and Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.1.1.1. Active Degraders (PROTACs)
14.5.1.1.2. LYTAC (Lysosome Targeting Chimera) Technology
14.5.1.1.3. Autophagosome-tethering Compound (ATTEC)
14.5.1.1.4. Autophagy-targeting Chimera (AUTAC) System
14.5.1.1.5. TAG Degradation Platform (aTAG, dTAG)
14.5.1.1.6. Degrader Building Blocks
14.5.1.1.7. Ubiquitin Proteasome System Proteins and Assays
14.5.1.1.8. Assays for Protein Degradation
14.5.1.1.9. Custom Degrader Services
14.5.1.1.10. SARDs and SERDs
14.5.1.1.11. Others
14.5.1.2. Saudi Arabia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
14.5.1.2.1. Intracellular Proteins
14.5.1.2.2. Extracellular Proteins; Transmembrane Proteins
14.5.1.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
14.5.1.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
14.5.1.3. Saudi Arabia Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
14.5.1.3.1. Breast Cancer
14.5.1.3.2. Colorectal Cancer
14.5.1.3.3. Prostate Cancer
14.5.1.3.4. Alzheimer's disease
14.5.1.3.5. Liver Fibrosis
14.5.1.3.6. Parkinson's disease
14.5.1.3.7. Psoriasis
14.5.1.3.8. Rheumatoid Arthritis
14.5.1.3.9. Autoimmune Diseases
14.5.1.3.10. Others
14.5.2. UAE
14.5.2.1. UAE Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.2.1.1. Active Degraders (PROTACs)
14.5.2.1.2. LYTAC (Lysosome Targeting Chimera) Technology
14.5.2.1.3. Autophagosome-tethering Compound (ATTEC)
14.5.2.1.4. Autophagy-targeting Chimera (AUTAC) System
14.5.2.1.5. TAG Degradation Platform (aTAG, dTAG)
14.5.2.1.6. Degrader Building Blocks
14.5.2.1.7. Ubiquitin Proteasome System Proteins and Assays
14.5.2.1.8. Assays for Protein Degradation
14.5.2.1.9. Custom Degrader Services
14.5.2.1.10. SARDs and SERDs
14.5.2.1.11. Others
14.5.2.2. UAE Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
14.5.2.2.1. Intracellular Proteins
14.5.2.2.2. Extracellular Proteins; Transmembrane Proteins
14.5.2.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
14.5.2.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
14.5.2.3. UAE Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
14.5.2.3.1. Breast Cancer
14.5.2.3.2. Colorectal Cancer
14.5.2.3.3. Prostate Cancer
14.5.2.3.4. Alzheimer's disease
14.5.2.3.5. Liver Fibrosis
14.5.2.3.6. Parkinson's disease
14.5.2.3.7. Psoriasis
14.5.2.3.8. Rheumatoid Arthritis
14.5.2.3.9. Autoimmune Diseases
14.5.2.3.10. Others
14.5.3. Egypt
14.5.3.1. Egypt Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.3.1.1. Active Degraders (PROTACs)
14.5.3.1.2. LYTAC (Lysosome Targeting Chimera) Technology
14.5.3.1.3. Autophagosome-tethering Compound (ATTEC)
14.5.3.1.4. Autophagy-targeting Chimera (AUTAC) System
14.5.3.1.5. TAG Degradation Platform (aTAG, dTAG)
14.5.3.1.6. Degrader Building Blocks
14.5.3.1.7. Ubiquitin Proteasome System Proteins and Assays
14.5.3.1.8. Assays for Protein Degradation
14.5.3.1.9. Custom Degrader Services
14.5.3.1.10. SARDs and SERDs
14.5.3.1.11. Others
14.5.3.2. Egypt Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
14.5.3.2.1. Intracellular Proteins
14.5.3.2.2. Extracellular Proteins; Transmembrane Proteins
14.5.3.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
14.5.3.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
14.5.3.3. Egypt Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
14.5.3.3.1. Breast Cancer
14.5.3.3.2. Colorectal Cancer
14.5.3.3.3. Prostate Cancer
14.5.3.3.4. Alzheimer's disease
14.5.3.3.5. Liver Fibrosis
14.5.3.3.6. Parkinson's disease
14.5.3.3.7. Psoriasis
14.5.3.3.8. Rheumatoid Arthritis
14.5.3.3.9. Autoimmune Diseases
14.5.3.3.10. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.4.1.1. Active Degraders (PROTACs)
14.5.4.1.2. LYTAC (Lysosome Targeting Chimera) Technology
14.5.4.1.3. Autophagosome-tethering Compound (ATTEC)
14.5.4.1.4. Autophagy-targeting Chimera (AUTAC) System
14.5.4.1.5. TAG Degradation Platform (aTAG, dTAG)
14.5.4.1.6. Degrader Building Blocks
14.5.4.1.7. Ubiquitin Proteasome System Proteins and Assays
14.5.4.1.8. Assays for Protein Degradation
14.5.4.1.9. Custom Degrader Services
14.5.4.1.10. SARDs and SERDs
14.5.4.1.11. Others
14.5.4.2. Kuwait Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
14.5.4.2.1. Intracellular Proteins
14.5.4.2.2. Extracellular Proteins; Transmembrane Proteins
14.5.4.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
14.5.4.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
14.5.4.3. Kuwait Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
14.5.4.3.1. Breast Cancer
14.5.4.3.2. Colorectal Cancer
14.5.4.3.3. Prostate Cancer
14.5.4.3.4. Alzheimer's disease
14.5.4.3.5. Liver Fibrosis
14.5.4.3.6. Parkinson's disease
14.5.4.3.7. Psoriasis
14.5.4.3.8. Rheumatoid Arthritis
14.5.4.3.9. Autoimmune Diseases
14.5.4.3.10. Others
14.5.5. South Africa
14.5.5.1. South Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.5.1.1. Active Degraders (PROTACs)
14.5.5.1.2. LYTAC (Lysosome Targeting Chimera) Technology
14.5.5.1.3. Autophagosome-tethering Compound (ATTEC)
14.5.5.1.4. Autophagy-targeting Chimera (AUTAC) System
14.5.5.1.5. TAG Degradation Platform (aTAG, dTAG)
14.5.5.1.6. Degrader Building Blocks
14.5.5.1.7. Ubiquitin Proteasome System Proteins and Assays
14.5.5.1.8. Assays for Protein Degradation
14.5.5.1.9. Custom Degrader Services
14.5.5.1.10. SARDs and SERDs
14.5.5.1.11. Others
14.5.5.2. South Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
14.5.5.2.1. Intracellular Proteins
14.5.5.2.2. Extracellular Proteins; Transmembrane Proteins
14.5.5.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
14.5.5.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
14.5.5.3. South Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
14.5.5.3.1. Breast Cancer
14.5.5.3.2. Colorectal Cancer
14.5.5.3.3. Prostate Cancer
14.5.5.3.4. Alzheimer's disease
14.5.5.3.5. Liver Fibrosis
14.5.5.3.6. Parkinson's disease
14.5.5.3.7. Psoriasis
14.5.5.3.8. Rheumatoid Arthritis
14.5.5.3.9. Autoimmune Diseases
14.5.5.3.10. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.6.1.1. Active Degraders (PROTACs)
14.5.6.1.2. LYTAC (Lysosome Targeting Chimera) Technology
14.5.6.1.3. Autophagosome-tethering Compound (ATTEC)
14.5.6.1.4. Autophagy-targeting Chimera (AUTAC) System
14.5.6.1.5. TAG Degradation Platform (aTAG, dTAG)
14.5.6.1.6. Degrader Building Blocks
14.5.6.1.7. Ubiquitin Proteasome System Proteins and Assays
14.5.6.1.8. Assays for Protein Degradation
14.5.6.1.9. Custom Degrader Services
14.5.6.1.10. SARDs and SERDs
14.5.6.1.11. Others
14.5.6.2. Rest of Middle East & Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
14.5.6.2.1. Intracellular Proteins
14.5.6.2.2. Extracellular Proteins; Transmembrane Proteins
14.5.6.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
14.5.6.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
14.5.6.3. Rest of Middle East & Africa Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
14.5.6.3.1. Breast Cancer
14.5.6.3.2. Colorectal Cancer
14.5.6.3.3. Prostate Cancer
14.5.6.3.4. Alzheimer's disease
14.5.6.3.5. Liver Fibrosis
14.5.6.3.6. Parkinson's disease
14.5.6.3.7. Psoriasis
14.5.6.3.8. Rheumatoid Arthritis
14.5.6.3.9. Autoimmune Diseases
14.5.6.3.10. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Offering
14.6.3. By Potential Targets
14.6.4. By Type of Diseases
15. Latin America Targeted Protein Degradation Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin America Targeted Protein Degradation Market Revenue (US$ Mn)
15.2. Latin America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
15.2.1. Active Degraders (PROTACs)
15.2.2. LYTAC (Lysosome Targeting Chimera) Technology
15.2.3. Autophagosome-tethering Compound (ATTEC)
15.2.4. Autophagy-targeting Chimera (AUTAC) System
15.2.5. TAG Degradation Platform (aTAG, dTAG)
15.2.6. Degrader Building Blocks
15.2.7. Ubiquitin Proteasome System Proteins and Assays
15.2.8. Assays for Protein Degradation
15.2.9. Custom Degrader Services
15.2.10. SARDs and SERDs
15.2.11. Others
15.3. Latin America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
15.3.1. Intracellular Proteins
15.3.2. Extracellular Proteins; Transmembrane Proteins
15.3.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
15.3.4. Intracellular Proteins; Non-protein Autophagy Substrates
15.4. Latin America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
15.4.1. Breast Cancer
15.4.2. Colorectal Cancer
15.4.3. Prostate Cancer
15.4.4. Alzheimer's disease
15.4.5. Liver Fibrosis
15.4.6. Parkinson's disease
15.4.7. Psoriasis
15.4.8. Rheumatoid Arthritis
15.4.9. Autoimmune Diseases
15.4.10. Others
15.5. Latin America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.1.1.1. Active Degraders (PROTACs)
15.5.1.1.2. LYTAC (Lysosome Targeting Chimera) Technology
15.5.1.1.3. Autophagosome-tethering Compound (ATTEC)
15.5.1.1.4. Autophagy-targeting Chimera (AUTAC) System
15.5.1.1.5. TAG Degradation Platform (aTAG, dTAG)
15.5.1.1.6. Degrader Building Blocks
15.5.1.1.7. Ubiquitin Proteasome System Proteins and Assays
15.5.1.1.8. Assays for Protein Degradation
15.5.1.1.9. Custom Degrader Services
15.5.1.1.10. SARDs and SERDs
15.5.1.1.11. Others
15.5.1.2. Brazil Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
15.5.1.2.1. Intracellular Proteins
15.5.1.2.2. Extracellular Proteins; Transmembrane Proteins
15.5.1.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
15.5.1.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
15.5.1.3. Brazil Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
15.5.1.3.1. Breast Cancer
15.5.1.3.2. Colorectal Cancer
15.5.1.3.3. Prostate Cancer
15.5.1.3.4. Alzheimer's disease
15.5.1.3.5. Liver Fibrosis
15.5.1.3.6. Parkinson's disease
15.5.1.3.7. Psoriasis
15.5.1.3.8. Rheumatoid Arthritis
15.5.1.3.9. Autoimmune Diseases
15.5.1.3.10. Others
15.5.2. Argentina
15.5.2.1. Argentina Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.2.1.1. Active Degraders (PROTACs)
15.5.2.1.2. LYTAC (Lysosome Targeting Chimera) Technology
15.5.2.1.3. Autophagosome-tethering Compound (ATTEC)
15.5.2.1.4. Autophagy-targeting Chimera (AUTAC) System
15.5.2.1.5. TAG Degradation Platform (aTAG, dTAG)
15.5.2.1.6. Degrader Building Blocks
15.5.2.1.7. Ubiquitin Proteasome System Proteins and Assays
15.5.2.1.8. Assays for Protein Degradation
15.5.2.1.9. Custom Degrader Services
15.5.2.1.10. SARDs and SERDs
15.5.2.1.11. Others
15.5.2.2. Argentina Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
15.5.2.2.1. Intracellular Proteins
15.5.2.2.2. Extracellular Proteins; Transmembrane Proteins
15.5.2.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
15.5.2.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
15.5.2.3. Argentina Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
15.5.2.3.1. Breast Cancer
15.5.2.3.2. Colorectal Cancer
15.5.2.3.3. Prostate Cancer
15.5.2.3.4. Alzheimer's disease
15.5.2.3.5. Liver Fibrosis
15.5.2.3.6. Parkinson's disease
15.5.2.3.7. Psoriasis
15.5.2.3.8. Rheumatoid Arthritis
15.5.2.3.9. Autoimmune Diseases
15.5.2.3.10. Others
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.3.1.1. Active Degraders (PROTACs)
15.5.3.1.2. LYTAC (Lysosome Targeting Chimera) Technology
15.5.3.1.3. Autophagosome-tethering Compound (ATTEC)
15.5.3.1.4. Autophagy-targeting Chimera (AUTAC) System
15.5.3.1.5. TAG Degradation Platform (aTAG, dTAG)
15.5.3.1.6. Degrader Building Blocks
15.5.3.1.7. Ubiquitin Proteasome System Proteins and Assays
15.5.3.1.8. Assays for Protein Degradation
15.5.3.1.9. Custom Degrader Services
15.5.3.1.10. SARDs and SERDs
15.5.3.1.11. Others
15.5.3.2. Rest of Latin America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Potential Targets
15.5.3.2.1. Intracellular Proteins
15.5.3.2.2. Extracellular Proteins; Transmembrane Proteins
15.5.3.2.3. Intracellular Proteins; Damaged Organelles Associated with Specific Proteins
15.5.3.2.4. Intracellular Proteins; Non-protein Autophagy Substrates
15.5.3.3. Rest of Latin America Targeted Protein Degradation Market Revenue (US$ Mn) and Forecasts, By Type of Diseases
15.5.3.3.1. Breast Cancer
15.5.3.3.2. Colorectal Cancer
15.5.3.3.3. Prostate Cancer
15.5.3.3.4. Alzheimer's disease
15.5.3.3.5. Liver Fibrosis
15.5.3.3.6. Parkinson's disease
15.5.3.3.7. Psoriasis
15.5.3.3.8. Rheumatoid Arthritis
15.5.3.3.9. Autoimmune Diseases
15.5.3.3.10. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Offering
15.6.3. By Potential Targets
15.6.4. By Type of Diseases
16. Competitive Benchmarking
16.1. Market Share Analysis, 2021
16.2. Global Presence and Growth Strategies
16.2.1. Mergers and Acquisitions
16.2.2. Product Launches
16.2.3. Investments Trends
16.2.4. R&D Initiatives
17. Player Profiles
17.1. Almac Group
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Amgen Inc.
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. Arvinas
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Bayer AG
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. C4 Therapeutics
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Captor Therapeutics
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. Genentech, Inc.
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. GlaxoSmithKline plc.
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. KYMERA THERAPEUTICS
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Promega Corporation
17.10.1. Company Details
17.10.2. Company Overview
17.10.3. Product Offerings
17.10.4. Key Developments
17.10.5. Financial Analysis
17.10.6. SWOT Analysis
17.10.7. Business Strategies
17.11. Other Market Participants
18. Key Findings
Note: This
ToC is tentative and can be changed according to the research study conducted
during the course of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
